Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 45055 

whether the methodology and 

assumptions used to determine the 

estimates are logical; (e) ways to 

enhance the quality, utility, and clarity 

of the information being collected; and 

(f) ways to minimize the public burden 

through the use of automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Send Comments and Requests for 

Further Information: Send your written 

comments, requests for more 

information on the proposed collection, 

or requests to obtain a copy of the data 

collection instrument(s) and 

instructions to: Mrs. Chris Rouleau, IHS 

Reports Clearance Officer, 801 

Thompson Ave., Suite 450, Rockville, 

MD 20852–1601; call non-toll free (301) 

443–5938; send via facsimile to (301) 

443–2316; or send your e-mail requests, 

comments, and return address to: 

Christina.Rouleau@ihs.gov. 

Comment Due Date: Your comments 

regarding this information collection are 

best assured of having full effect if 

received within 60 days of the date of 

this publication. 

Dated: August 3, 2007. 

Charles W. Grim, 

Assistant Surgeon General, Director, Indian 

Health Service. 

[FR Doc. 07–3895 Filed 8–9–07; 8:45 am] 

BILLING CODE 4165–16–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Treatment for Cystic Fibrosis Cells and 

Other Reduced ClØConductance Cells 

Description of Technology: Cystic 

fibrosis is the most common fatal 

genetic disease among Caucasians. It is 

caused by a defect in the cystic fibrosis 

transmembrane regulator (CFTR) 

protein. A normal CFTR transports 

chloride ions across the membrane of 

epithelial cells lining several organs in 

the body such as the lungs and the 

pancreas. The most debilitating 

consequence of the defective CFTR 

protein occurs in the lungs of cystic 

fibrosis patients, where insufficient 

chloride transport prevents water from 

exiting epithelial cells. This causes the 

lungs to produce abnormally thick, 

sticky mucus that clogs the airways and 

leads to fatal lung infections. Currently 

there is no cure for the disease. Present 

treatments result in undesired side 

effects such as cardiac, renal, and/or 

central nervous system tissue. 

The NIH has developed a method of 

identifying cystic fibrosis 

transmembrane regulator binding 

compounds for treating cells having a 

reduced Cl¥conductance, such as 

cystic fibrosis cells. It has also identified 

a compound, 1,3-Diallyl-8- 

cyclohexylxanthine (DAX), for potential 

treatment of cystic fibrosis. Because 

DAX has specificity in target areas of 

activity, treatment with this compound 

can potentially prevent all of the 

complications of cystic fibrosis 

including the production of abnormal 

mucus and without undesired side 

effects. DAX is active in extremely low 

concentrations. 

Applications: Diagnostic; Therapeutic 

agent for the treatment of cells having a 

reduced Cl¥conductance. 

Market: This is intended for cystic 

fibrosis or other reduced 

Cl¥conductance cells; Approximately 

70,000 children and young adults 

worldwide, including 30,000 in the U.S. 

and 30,000 in Europe. 

Development Status: Dr. Pollard has 

performed pre-clinical testing. 

Inventors: Dr. Harvey B. Pollard and 

Dr. Kenneth A. Jacobson (NIDDK). 

Publications: 

1. N Arispe et al. ‘‘Direct activation of 

cystic fibrosis transmembrane 

conductance regulator channels by 8–

cyclopentyl–1,3–dipropylxanthine 

(CPX) and 1,3–diallyl–8–

cyclohexylxanthine (DAX),’’ J Biol 

Chem. 1998 Mar 6;273(10):5727–5734. 

2. KA Jacobson, C Guay-Broder, PJM 

van Galen, C Gallo-Rodriguez, N 

Melman, O Eidelman, HB Pollard. 

‘‘Stimulation by alkylxanthines of 

chloride efflux in CFPAC-cells does not 

involve A1-adenosine receptors,’’

Biochemistry, 1995 Jul 18;34(28):9088–

9094. 

Patent Status: 

U.S. Patent No. 5,877,179 issued 02 

Mar 1999 (HHS Reference No. E–138–

1992/1–US–01). This patent is for 

identifying binding compounds and 

composition of matter. 

U.S. Patent No. 6,083,954 issued 04 

Jul 2000 (HHS Reference No. E–138–

1992/1–US–02). This patent is for 

treating CF. 

Foreign patent rights available. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Catherine A. 

Wendelken; 301/435–5282; 

wendelkenc@od.nih.gov. 

Dated: August 3, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–15622 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Research Program Project on Hypertension in 

Youth. 

Date: September 7, 2007. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Washington, 1515 

Rhode Island Ave., NW., Washington, DC 

20005. 

Contact Person: Holly Patton, PhD, 

Scientific Review Administrator, Review 


sroberts on PROD1PC70 with PROPOSALS
45056 Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7188, Bethesda, MD 20892–7924. (301) 435–

0280, pattonh@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: August 2, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3899 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Heart, Lung, and Blood 

Advisory Council. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: September 12, 2007. 

Time: 12:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Stephen Mockrin, PhD, 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6701 

Rockledge Drive, Room 7100, Bethesda, MD 

20892, (301) 435–0260 

mockrins@nhlbi.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: August 2, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3900 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: NIDCR Special Grants 

Review Committee, Mtg 08–01, Review R03s, 

Fs, Ks. 

Date: October 11–12, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Raj Krishnaraju, PhD, MS, 

Scientific Review Administrator, Scientific 

Review Branch, National Inst. of Dental & 

Craniofacial Research, National Institutes of 

Health, 45 Center Dr. Rm 4AN 32J, Bethesda, 

MD 20892, 301–594–4864, 

kkrishna@nidcr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: August 2, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3901 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets of commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council. 

Date: September 20–21, 2007. 

Open: September 20, 2007, 10:30 a.m. to 5 

p.m. 

Agenda: Report by the Director, NINDS; 

Report by the Director, Division of 

Extramural Research and other 

administratrive and program developments. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Closed: September 21, 2007, 8 a.m. to 11 

a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Robert Finkelstein, PhD, 

Associate Director for Extramural Research, 

National Institute of Neurological Disorders 

and Stroke, NIH, 6001 Executive Blvd., Suite 

3309, MSC 9531, Bethesda, MD 20892, (301) 

496–9248. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 


sroberts on PROD1PC70 with PROPOSALS